Tribesta is an original, non-hormonal drug. Its active components are
non-steroid saponins, offurostanol type, isolated from the plant Tribulus Terrestris.
A pronounced stimulating effect on spermatogenesis
is observed after the drug is administered orally to sexually mature rats.
Increased number of spermatogonia,spermatocyte, spermatid and mature spermatozoid in the testes has been observed without widening of the diameter of the seminiferous tubules.
In parallels, increased number of Sertoli cells is observed in a volume unit from rat testes. Oral administration stimulates the mitotic activity of spermatogonia in mature rats.
Oral administration of the drug leads to intensification of spermatogenesis and enhancement of the quality of spermatozoa in sexually mature rats.
The percentage of motile spermatozoa increases, the characteristic of their motility improve, prolonging the period of their viability and at the same time, given orally to swine, Tribesta stimulates their sexual behavior.
The clinical trials of the drug have also confirmed the experimental data.
Tribesta, administered to male subjects with disorders in the spermogram due to varico-cele, increases the volume of the ejaculated sperm by 1-2 ml, increases the spermatozoa concentration by 30 million/ml; increases the percentage of the motility by 30%.
The drug has a marked effect on the motility of spermatozoa in case of oligoasthenozoospermila, as revealed by the study of its therapeutic properties in man.
The mean number of motile spermatozoa in the group studies was 29% prior to the study, and later it reached up to 36.6%.
The motility rate of the spermatozoa prior to the treatment was 1.95 mm/sec and 3.76% mm/sec. Of definite interest is the treatment of patients with unilateral and bilateral hypotrophy of the testes combined with the disorders in the spermogram.
The libido was enhanced after 60-day Tribesta treatment and the characteristics of the spermogram were improved.
Recovery and enhanced libido were observed in patients with primary and secondary hypogonadism after Tribesta administration, as well as prolonged erection.
Both experimental and clinical studies reveal that drug is not toxic and induces no adverse effects.